<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00071058</url>
  </required_header>
  <id_info>
    <org_study_id>040011</org_study_id>
    <secondary_id>04-C-0011</secondary_id>
    <nct_id>NCT00071058</nct_id>
    <nct_alias>NCT00073996</nct_alias>
  </id_info>
  <brief_title>Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer</brief_title>
  <official_title>A Study of Combination Chemotherapy &amp; Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane &amp; Continuous Infusion Doxorubicin, Vincristine &amp; Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before &amp; After Surgical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and effectiveness of treating adrenocortical cancer with
      combination chemotherapy using doxorubicin, vincristine, and etoposide in addition to the
      drugs mitotane and tariquidar and, when possible, surgery. Adrenocortical cancer cells have a
      large amount of a protein called P-glycoprotein that &quot;pumps&quot; anti-cancer drugs out of the
      cells, decreasing their effectiveness. Continuous infusions of doxorubicin, vincristine, and
      etoposide may improve chemotherapy results by blocking the P-glycoprotein pump, as may use of
      tariquidar, an experimental drug that is known to block the P-glycoprotein pump.

      Patients 18 years of age and older with adrenocortical cancer that has recurred, spread, or
      cannot be treated surgically may be eligible for this study. Candidates will be screened with
      a medical history and physical examination; review of pathology slides; blood tests;
      electrocardiogram (EKG); imaging tests, including computed tomography (CT) of the chest,
      abdomen and pelvis; chest x-ray; and possibly a bone scan or other imaging tests needed to
      evaluate the cancer, urine studies, and an echocardiogram. Also, a biopsy (removal of a small
      sample of tumor tissue) may be required if a specimen is not available to confirm the cancer.

      Participants will undergo the following tests and procedures:

        -  Tumor biopsy. Before starting chemotherapy, a small piece of tumor is removed to study
           the P-glycoprotein pump and to determine the tumor genetics.

        -  Blood draw. Blood is drawn before treatment begins to establish baseline levels for
           future blood tests.

        -  Central venous catheter placement. A specially trained physician places a plastic tube
           into a major vein in the chest. The tube is used to give the study drugs and other
           medications and to withdraw blood samples. It can stay in the body for months or be
           removed after each treatment is completed. The tube placement is done under a local
           anesthetic in the radiology department or operating room.

        -  Chemotherapy. Treatment cycles are 21 days. Doxorubicin, vincristine, and etoposide are
           given through the central venous catheter by an infusion pump continuously over 96 hours
           starting day 1 of each cycle. The dose of these drugs may be increased or decreased from
           cycle to cycle, based on side effects. Mitotane is given in pill form starting day 1 of
           cycle 1 and is taken every day throughout the entire study. The mitotane dose is
           gradually increased as long as the side effects are tolerable. Tariquidar is given
           through the central venous catheter as a 30-minute infusion on days 1 and 3 of every
           cycle. The tariquidar dose remains the same throughout the study. Treatment will
           continue for two cycles after all the cancer is gone, or until surgery is done to remove
           some or all of the remaining cancer, or, if surgery is not an option, until the cancer
           has grown to where it is defined as progressive disease.

        -  Nuclear scans. A nuclear scan is done before treatment begins and again on day 1 or day
           3 of the first treatment cycle after administration of tariquidar to evaluate the P
           glycoprotein response to treatment.

        -  Computed tomography (CT) scans. These scans are done every two treatment cycles to
           follow disease progress.

        -  Surgery. Surgery to remove areas of cancer may be considered at any point during the
           study (including before beginning treatment), if it is deemed beneficial. Treatment with
           the study drugs will begin or resume after surgery. The length of treatment will depend
           on the response to treatment before the surgery and on whether there is any cancer
           remaining after the surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adrenocortical cancer (ACC) is a rare tumor that is optimally treated with surgical
      resection. However, many patients present with unresectable disease and relapses are common
      after surgical resection creating a need for more effective systemic therapies. Several
      investigators have reported responses to a variety of chemotherapy agents, without a clear
      improvement in overall survival. A possible explanation for these disappointing results is
      the high levels of expression of P-glycoprotein (Pgp) seen in a majority of adrenocortical
      cancers. Pgp, a membrane protein that can function as a drug efflux pump lowering the
      intracellular concentrations of various drugs, has been implicated as a mechanism of drug
      resistance.

      A prior National Cancer Institute (NCI) study (referred to as MAVE) tried to improve response
      rates by using a combined modality approach with chemotherapy and surgery. Prior in vitro
      studies had shown that mitotane inhibited Pgp and that continuous exposure to doxorubicin and
      vincristine was more effective at overcoming Pgp-mediated resistance than the same drugs
      given on an intermittent schedule. The MAVE study used daily oral mitotane with infusional
      doxorubicin, vincristine, and etoposide prior to tumor resection in patients with resectable
      or potentially resectable tumors. The results showed an overall response rate of 19%
      (including minor responses), and an overall median survival of 13.5 months. These results
      were similar to those reported with previous regimens in adrenocortical cancer (ACC). A
      possible explanation for the failure to achieve a higher response rate may be that mitotane
      was unable to inhibit Pgp. Although the serum levels of mitotane achieved in patients had
      been shown to block Pgp in vitro, inhibition of Pgp in patients was not accomplished, as
      documented by a validated surrogate assay using Pgp-expressing CD56+ cells and the Pgp
      substrate, rhodamine. Thus the question of whether Pgp inhibition would improve response
      rates remains unanswered.

      This trial will attempt to answer the latter question by using an agent, tariquidar (XR9576),
      which has been proven to inhibit Pgp in humans with minimal toxicity alone or in combination
      with chemotherapy. Tariquidar will be used with the regimen from the prior MAVE study in an
      effort to improve response rates and overall survival in patients with ACC whose options at
      this time are limited.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Partial or Complete Response</measure>
    <time_frame>Every 6 weeks for up to a year</time_frame>
    <description>Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Complete response is defined as the disappearance of all signs and symptoms of tumor for a period of at least 4 weeks. Partial response is defined as at least a 30% decrease in the sum of the longest diameter of all measured lesions lasting for a period of 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>60 months, 19 days</time_frame>
    <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Adrenal Cortex Neoplasms</condition>
  <arm_group>
    <arm_group_label>Surgery plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.
Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m^2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XR9576 (Tariquidar)</intervention_name>
    <arm_group_label>Surgery plus chemotherapy</arm_group_label>
    <other_name>150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Pathologic confirmation of adrenocortical cancer by the Laboratory of Pathology, NCI

        Diagnosis of recurrent, metastatic, or primary unresectable adrenocortical carcinoma.

        Measurable disease at presentation.

        A life expectancy of at least 3 months and Eastern Cooperative Oncology Group (ECOG)
        performance status less than or equal to 2.

        Age greater than or equal to 18 years.

        Last dose of chemotherapy or experimental therapy more than 4 weeks (6 weeks in the case of
        nitrosourea) prior to enrollment date.

        Last radiotherapy treatment 4 weeks prior to starting treatment with this protocol and
        there must be sites of measurable disease that did not receive radiation.

        Prior mitotane therapy is allowed. Patients do not need to be off mitotane therapy prior to
        starting this protocol.

        Organ and marrow function as defined below:

          -  Total bilirubin less than or equal to 1.5 times ULN (upper limit of normal), unless
             the patient meets the criteria for Gilbert's Syndrome,

          -  Aspartate aminotransferase (AST) less than or equal to 3 times ULN, Alanine
             aminotransferase (ALT) less than or equal to 3 times ULN

          -  Creatinine clearance greater than or equal to 40 ml/min (measured in a timed urine
             collection) or serum creatinine less than or equal to 1.6 mg/dl

          -  Absolute neutrophil count greater than or equal to 1000/mm^3,

          -  Platelet count greater than or equal to 100,000/mm^3

        Ability to understand and sign an informed consent document.

        Ability and willingness to follow the guidelines of the clinical protocol including visits
        to National Cancer Institute (NCI), Bethesda, Maryland for treatment and follow up visits.

        The effects of chemotherapy on the developing human fetus are potentially harmful therefore
        women of childbearing potential and men must agree to use adequate contraception (hormonal
        or barrier methods) during the study and for a period of 1 month after the last dose of
        chemotherapy.

        EXCLUSION CRITERIA:

        Patients with adrenocortical tumors potentially curable by surgical excision alone as
        determined by the Principal Investigator in discussions with the surgical consultants.

        Uncontrolled illness including, but not limited to symptomatic congestive heart failure,
        unstable angina pectoris, seizure disorder, or psychiatric illness that may limit
        compliance with study requirements. These illnesses may be exacerbated by chemotherapy.

        Untreated brain metastases (or local treatment of brain metastases within the last 6
        months) due to the poor prognosis of these patients and difficulty ascertaining the cause
        of neurologic toxicities.

        Pregnancy due to the possible adverse effects on the developing fetus.

        Lactating women who are breast-feeding due to the possibility of transmitting chemotherapy
        to the child.

        The presence of a second malignancy, other than squamous cell carcinoma of the skin or in
        situ cervical cancer because it will complicate the primary objective of the study. Cancer
        survivors who have been free of disease for at least two years can be enrolled in this
        study.

        Currently receiving treatment (which cannot be discontinued) with the following agents:
        diltiazem, nicardipine, phenothiazines, phenytoin, or verapamil because these are Pgp
        inhibitors and will interfere with the primary objective of the study.

        Ejection fraction less than 40% as determined by multi-gated acquisition scan (MUGA),
        echocardiogram (Echo), or cardiac magnetic resonance imaging (MRI) in patients with a
        clinical history suggestive of systolic dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Fojo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/A_2004-C-0011.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Cohn K, Gottesman L, Brennan M. Adrenocortical carcinoma. Surgery. 1986 Dec;100(6):1170-7.</citation>
    <PMID>3787475</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2003</study_first_submitted>
  <study_first_submitted_qc>October 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2003</study_first_posted>
  <results_first_submitted>August 13, 2012</results_first_submitted>
  <results_first_submitted_qc>August 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2012</results_first_posted>
  <last_update_submitted>September 12, 2012</last_update_submitted>
  <last_update_submitted_qc>September 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2012</last_update_posted>
  <responsible_party>
    <name_title>Antonio Fojo, M.D./National Cancer Institute</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>P-glycoprotein Inhibition</keyword>
  <keyword>Drug Resistance Reversal</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Molecular Target</keyword>
  <keyword>Endocrine Cancer</keyword>
  <keyword>Adrenocortical Cancer</keyword>
  <keyword>ACC</keyword>
  <keyword>Adrenocortical Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Cortex Neoplasms</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mitotane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Surgery Plus Chemotherapy</title>
          <description>Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.
Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m^2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>brain tumor-removed from study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Surgery Plus Chemothrapy</title>
          <description>Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.
Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.56" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Partial or Complete Response</title>
        <description>Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Complete response is defined as the disappearance of all signs and symptoms of tumor for a period of at least 4 weeks. Partial response is defined as at least a 30% decrease in the sum of the longest diameter of all measured lesions lasting for a period of 4 weeks.</description>
        <time_frame>Every 6 weeks for up to a year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surgery Plus Chemotherapy</title>
            <description>Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.
Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Partial or Complete Response</title>
          <description>Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Complete response is defined as the disappearance of all signs and symptoms of tumor for a period of at least 4 weeks. Partial response is defined as at least a 30% decrease in the sum of the longest diameter of all measured lesions lasting for a period of 4 weeks.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
        <time_frame>60 months, 19 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surgery Plus Chemotherapy</title>
            <description>Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.
Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m^2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Surgery Plus Chemothrapy</title>
          <description>Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.
Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac left ventricular function</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia (painful swallowing)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ileus (or neuroconstipation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Abdominal pain or cramping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection) (ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>(documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="176" subjects_affected="47" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="62" subjects_affected="34" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="101" subjects_affected="45" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="109" subjects_affected="33" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Prothrombin time (PT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hematuria (in the absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cardiac left ventricular function</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Peripheral arterial ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Earache (otalgia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tearing (watery eyes)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="56" subjects_affected="33" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="45" subjects_affected="28" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" events="56" subjects_affected="28" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia (painful swallowing)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ileus (or neuroconstipation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="91" subjects_affected="42" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis)</sub_title>
                <counts group_id="E1" events="61" subjects_affected="30" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Taste disturbance (dysgeusia)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="54" subjects_affected="30" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Abdominal pain or cramping</sub_title>
                <counts group_id="E1" events="29" subjects_affected="19" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rectal or perirectal pain (proctalgia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other (Specify, dental extraction; early satiety; bloating)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="111" subjects_affected="44" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>(in the absence of neutropenia, where neutropenia is defined as AGC&lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rigors, chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Chest pain (non-cardiac and non-pleuritic)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain-Other (Specify, Back Pain; Neck; Flank R; Pain in right rib )</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="22" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="55" subjects_affected="25" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>SGOT (AST) (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="58" subjects_affected="26" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="52" subjects_affected="23" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection) (ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>(documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="16" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection/Febrile Neutropenia-Other (Specify, vag. yeast infection)</sub_title>
                <description>&quot;Thrush&quot;, zoster, herpes L butt</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="23" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal-Other (Specify, fracture of L. fibula)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Arthralgia (joint pain)</sub_title>
                <counts group_id="E1" events="93" subjects_affected="33" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Myalgia (muscle pain)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mood alteration-anxiety, agitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mood alteration-depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neurology-Other (Specify, largyngitis, voice hoarseness; neurology: Tinnitus L&gt;R )</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neuropathy - motor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="48" subjects_affected="29" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginitis (not due to infection)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sexual/Reproductive Function-Other (Specify, Amenorrhea)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Voice changes/stridor/larynx (e.g., hoarseness, loss of voice, laryngitis)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bruising (in absence of grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pigmentation changes (e.g., vitiligo)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin-Other (Specify, Head Rash; pain: port problems, pain, redness )</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Antonio Fojo, M.D.</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-2631</phone>
      <email>FojoT@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

